Tarsus Pharmaceuticals IncNASDAQ:TARS
- LAST PRICE11.9200
- TODAY'S CHANGE (%)-0.2200 (-1.8122%)
- Bid / Lots4.7500/ 2
- Ask / Lots18.9900/ 2
- Open / Previous Close12.0400 / 12.1400
- Day Range
- 52 Week Range
- Volume76,413
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TARS |
|---|---|---|
| 09:32 ET | 172 | 12.04 |
| 09:45 ET | 100 | 11.9 |
| 09:50 ET | 420 | 12.05 |
| 09:56 ET | 300 | 12.005 |
| 09:57 ET | 100 | 12 |
| 10:06 ET | 2792 | 12.005 |
| 10:08 ET | 410 | 11.93 |
| 10:15 ET | 100 | 12.005 |
| 10:33 ET | 261 | 12.01 |
| 10:35 ET | 1200 | 11.95 |
| 10:44 ET | 400 | 12 |
| 10:48 ET | 1600 | 11.985 |
| 10:50 ET | 200 | 11.97 |
| 10:53 ET | 500 | 11.86 |
| 11:06 ET | 337 | 12.0101 |
| 11:08 ET | 160 | 11.965 |
| 11:11 ET | 100 | 11.96 |
| 11:26 ET | 200 | 11.89 |
| 11:31 ET | 400 | 11.89 |
| 11:42 ET | 800 | 11.88 |
| 11:45 ET | 100 | 11.88 |
| 11:54 ET | 400 | 11.88 |
| 11:58 ET | 100 | 11.875 |
| 12:02 ET | 100 | 11.885 |
| 12:18 ET | 200 | 11.94 |
| 12:20 ET | 400 | 11.88 |
| 12:56 ET | 100 | 11.88 |
| 12:59 ET | 100 | 11.91 |
| 01:12 ET | 200 | 11.9 |
| 01:19 ET | 200 | 11.86 |
| 01:24 ET | 100 | 11.9 |
| 01:32 ET | 200 | 11.905 |
| 01:46 ET | 500 | 11.97 |
| 01:55 ET | 100 | 12.01 |
| 02:13 ET | 100 | 11.97 |
| 02:33 ET | 100 | 11.98 |
| 02:36 ET | 3261 | 11.88 |
| 02:44 ET | 357 | 11.79 |
| 02:47 ET | 100 | 11.79 |
| 02:54 ET | 197 | 11.7884 |
| 02:56 ET | 100 | 11.785 |
| 03:02 ET | 100 | 11.79 |
| 03:05 ET | 1193 | 11.85 |
| 03:07 ET | 1120 | 11.84 |
| 03:09 ET | 200 | 11.855 |
| 03:12 ET | 400 | 11.85 |
| 03:14 ET | 100 | 11.85 |
| 03:16 ET | 200 | 11.855 |
| 03:18 ET | 1600 | 11.89 |
| 03:20 ET | 1100 | 11.915 |
| 03:23 ET | 100 | 11.945 |
| 03:27 ET | 100 | 11.965 |
| 03:30 ET | 100 | 11.965 |
| 03:32 ET | 100 | 12 |
| 03:34 ET | 229 | 11.965 |
| 03:36 ET | 100 | 12 |
| 03:38 ET | 4846 | 12 |
| 03:39 ET | 500 | 11.96 |
| 03:41 ET | 300 | 11.97 |
| 03:48 ET | 100 | 11.94 |
| 03:50 ET | 100 | 11.96 |
| 03:52 ET | 260 | 11.92 |
| 03:54 ET | 1000 | 11.85 |
| 03:56 ET | 462 | 11.86 |
| 03:57 ET | 596 | 11.87 |
| 03:59 ET | 12437 | 11.92 |
Mar 13, 2023
BRIEF-Tarsus Reports Full-Year 2022 Financial Results And Recent Business Achievements, from 4:14PM ET on Monday Mar 13, 2023 by Thomson Reuters
4:14PM ET on Monday Mar 13, 2023 by Thomson ReutersTarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements, from 4:05PM ET on Monday Mar 13, 2023 by GlobeNewswire
4:05PM ET on Monday Mar 13, 2023 by GlobeNewswire
Mar 2, 2023
Tarsus to Present at Upcoming Investor Conferences, from 4:30PM ET on Thursday Mar 02, 2023 by GlobeNewswire
4:30PM ET on Thursday Mar 02, 2023 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Tarsus Pharmaceuticals Inc | 324.5M | -4.6x | --- |
AVITA Medical Inc | 325.6M | -12.0x | --- |
Voyager Therapeutics Inc | 323.8M | -6.1x | --- |
Alpine Immune Sciences Inc | 372.8M | -4.2x | --- |
Autolus Therapeutics PLC | 323.6M | -1.1x | --- |
Stoke Therapeutics Inc | 347.4M | -2.9x | --- |
Company Information
Tarsus Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapeutics. The Company’s lead product candidate, TP-03, is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites (Demodex blepharitis). The Company designs TP-03 to target and eradicate the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient of TP-03, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. It is also focused on investigating the development of product candidates to address targeted diseases with high unmet medical needs, which include TP-03 for the potential treatment of Meibomian Gland Disease (MGD), TP-04 for the potential treatment of rosacea, and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
Contact Information
- Headquarters
- 15440 Laguna Canyon RoadIRVINE, CA, United States 92618
- Phone
- 949-409-9820
- Fax
- 302-531-3150
Executives
- Chairman of the Board, President, Chief Executive Officer, Co-Founder
- Bobak Azamian
- Chief Financial Officer
- Leo Greenstein
- Chief Operating Officer
- Seshadri Neervannan
- Chief Human Resources Officer
- Dianne Whitfield
- Senior Vice President - Clinical Affairs
- Mark Holdbrook
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $324.5M |
|---|---|
Revenue (TTM) | $25.8M |
Shares Outstanding | 26.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.57 |
Book Value | $7.22 |
P/E Ratio | -4.6x |
Price/Sales (TTM) | 12.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -242.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
